Manufacturer for the pharma and life sciences industry, Gerresheimer, is investing more than $88 million to expand its operations in Peachtree City, Georgia.
Clinical-stage drug delivery and development company DelSiTech has made the biggest single financing round in its history with the successful completion of a €10 million deal.
The company has landed funding from the Bill and Melinda Gates Foundation for research and development on a prototype of a refillable contraceptive solution.
The company reports dosing of the first subject in a Phase IIa proof-of-concept study investigating a drug for an autism spectrum disorder related condition.
A report from the industry event’s organizers indicates American companies have an edge on drug delivery innovation but lag in operational sustainability.
On May 5, a panel of experienced industry experts will discuss recent developments during Innovations in Drug Delivery, a free one-hour industry webinar.
Developers of generic drugs administered with topical drug delivery methods benefit from MedPharm’s in-vitro models to safely demonstrate bioequivalence.
While exhibiting its offering in self-administration devices at the CPhI Worldwide event in Frankfurt last week, West told us how patient convenience drives design and development.
A drug is only as effective as its delivery system, and the advent of new molecules and new innovations have to be matched by enhanced delivery and containment methods, suggests West Pharma exec.
A study at Washington University in St. Louis has shown a new way to deliver drugs to the brainstem in a non-invasive administration: microbubbles and ultrasound.
Legal battles, patent acquisitions and R&D dominate in-pharmatechnologist.com’s round up of developments in drug delivery this week with news from MonoSol, Acacia and a US University team working on GSK’s Relenza.
Eurand says Zenpap important to Q1 growth that recent FDA move provides the drug with significant potential for further expansion in cystic fibrosis (CF) market
US company DOR BioPharma plans to start clinical trials in the next
few months with what could be the first oral formulation of the
widely used prostate cancer treatment leuprolide.
When selecting a pharmaceutical formulation, the conventional
wisdom has been to manipulate a drug delivery platform to make it
compatible with a drug's properties, yet the opposite approach may
have several benefits if enough...
CyDex has won the first regulatory approval in Japan for a
pharmaceutical product using its Captisol drug delivery technology
designed to improve the delivery of insoluble and unstable active
pharmaceutical ingredients.
